Revvity Shares Drop 5.13% as Volume Surges to $210M Ranking 477th Amid China Diagnostics Slump and Analyst Downgrades

Revvity (RVTY) fell 5.13% on September 3, 2025, with a trading volume of $0.21 billion, up 81.1% from the previous day, ranking 477th in volume. The decline followed CFO Maxwell Krakowiak’s remarks at the Wells Fargo Healthcare Conference, highlighting 3% organic growth in Q2, driven by Life Sciences software and reagent growth. However, Diagnostics revenue faced a 15% quarterly drop in China due to reimbursement policy shifts, a challenge expected to persist into Q3 and require a full year to normalize.

Krakowiak noted tariffs imposed a $0.12 headwind to 2025 guidance, primarily affecting European-to-U.S. Diagnostics manufacturing. Life Sciences, accounting for a significant portion of revenue, showed resilience, with pharma and Signals business growth. The A&G segment, a quarter of Life Sciences revenue, declined slightly, though the U.S. market remains a smaller component. Analysts cited ongoing China-related pressures and macroeconomic headwinds as key risks to near-term performance.

The stock’s decline to a 52-week low of $85.01 reflects broader market sentiment amid profit-taking and rising Treasury yields, which reduced the appeal of equities. Despite Q2 earnings beating expectations, analyst downgrades from Stifel and Raymond James weighed on investor confidence. Revvity’s year-to-date drop of 25.3% underscores persistent concerns about China’s regulatory environment and global economic uncertainty.

Backtest results indicate Revvity’s volume surged to $0.21 billion on September 3, a 81.1% increase, while the stock closed 5.13% lower, aligning with the provided data.